Transcutaneous vaccination with virus-like particles

Vaccine

Volumn 24, Issue 26, 2006, Pages 5406-5412

  Young, Sarah L ^a   Wilson, Michelle ^a   Wilson, Sarah ^a   Beagley, Kenneth W ^b   Ward, Vernon ^a   Baird, Margaret A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Dendritic cells; Rabbit hemorrhagic disease virus; Transcutaneous vaccination; Virus like particles

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; PROTEIN VP60; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RABBIT HEMORRHAGIC DISEASE VIRUS; VACCINATION; VIRUS PARTICLE; VIRUS STRAIN;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, SURFACE; CAPSID; DENDRITIC CELLS; HEMORRHAGIC DISEASE VIRUS, RABBIT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; SPECIFIC PATHOGEN-FREE ORGANISMS; UP-REGULATION; VIRAL VACCINES; VIRION;

EID: 33744785387     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.052     Document Type: Article

References (28)

1. Hesseling A.C., Schaaf H.S., Hanekom W.A., Beyers N., Cotton M.F., Gie R.P., et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37 (2003) 1226-1233
2. Baird M., Wilson R., Young L., Williman J., Young S., Wilson M., et al. Bystander help within a polyepitope DNA vaccine improves immune responses to influenza antigens. Scand J Immunol 60 (2004) 363-371
3. Ali M., Emch M., von Seidlein L., Yunus M., Sack D.A., Rao M., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 (2005) 44-49
4. Huckriede A., Bungener L., Stegman T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 23 Suppl 1 (2005) S26-S38
5. Harper D.M., Franco E.L., Wheeler C., Ferris D., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
6. Nagesha H.S., Wang L.F., and Hyatt A.D. Virus-like particles of calicivirus as epitope carriers. Arch Virol 144 (1999) 2429-2439
7. Estes M.K., Ball J.M., Crawford S.E., O'Neal C., Opekun A.A., Graham D.Y., et al. Virus-like particle vaccines for mucosal immunization. Adv Exp Med Biol 412 (1997) 387-395
8. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., and Bachmann M.F. Nonmethylated CpG motifs packaged into virus-like particles induce protective cytotoxic cell responses in the absence of systemic side effects. J Immunol 172 (2004) 1777-1785
9. Laurent S., Vautherot J.F., Madelaine M.F., Le Gall G., and Rasschaert D. Recombinant Rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into virus-like particles and induces protection. J Virol 68 (1994) 6794-6798
10. Young S.L., Buchan G., Slobbe L.J., Williman J., Wilson M., Ward V., et al. Novel vaccine formulations to enhance Type 1 immune responses. Immunology 1 (2004) 555-563
11. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
12. Bachmann M.F., and Jennings G.T. Virus-like particles: combining innate and adaptive immunity for effective vaccination. In: Stefan Kaufmann (Ed). Novel Vaccine Strategies (2004)
13. El Mehdaoui S., Touze A., Laurent S., Sizaret P.Y., Rasschaert D., and Coursaget P. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16. J Virol 74 (2000) 10332-10340
14. Boes M., and Ploegh H.L. Translating cell biology in vitro into immunity in vivo. Nature 430 (2004) 264-271
15. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunisation with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72 (2004) 1019-1028
16. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognises bacterial DNA. Nature 408 (2000) 740-745
17. Starnbach M.N., Bevan M.J., and Lampe M.F. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J Immunol 153 (1994) 5183-5189
18. Krieg A.M., and Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3 (2001) 15-24
19. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., and Takigawa M. Percutaneous peptide immunisation via corneum barrier-disrupted murine skin for experimental tumour immunoprophylaxis. Proc Natl Acad Sci USA 97 (2000) 371-376
20. Partidos C.D., Beignon A., Briand J., and Muller S. Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22 (2004) 2385-2390
21. Salmond R.J., Luross J.A., and Williams N.A. Immune modulation by the cholera-like enterotoxins. Expert Rev Mol Med 2002 (2002) 1-16
22. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., and Berzofsky J.A. Transcutaneous immunisation induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113 (2004) 998-1007
23. Jakob T., Walker P.S., Krieg A.M., Udey M.C., and Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161 (1998) 3042-3049
24. Hickey D.K., Bao S., Ikeda L.T., Carey A.J., and Beagley K.W. Induction of anti-chlamydial mucosal immunity by transcutaneous immunisation is enhanced by topical application of GM-CSF. Curr Mol Med 5 6 (2005) 599-605
25. Tergerstedt K., Franzen A.V., Andreasson K., Joneberg J., Heidari S., Ramqvist T., et al. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Anticancer Res 25 (2005) 2601-2608
26. Kelly K.A. Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms. Int Rev Immunol 22 (2003) 3-41
27. Beagley K.W., and Timms P. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol 48 (2000) 47-68
28. Rothfuchs A.G., Kreuger M.R., Wigzell H., Rottenberg M.E., and Macrophages. CD4+ or CD8+ cells are sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-γ. J Immunol 172 (2004) 2407-2415